NASDAQ:CRON Cronos Group Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cronos Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.29 +0.05 (+0.95 %) (As of 09/18/2020 09:20 PM ET) Add Compare Share Today's Range$5.20Now: $5.29▼$5.3450-Day Range$5.21MA: $5.65▼$7.0852-Week Range$4.00Now: $5.29▼$10.96Volume2.18 million shsAverage Volume6.22 million shsMarket Capitalization$1.85 billionP/E Ratio11.76Dividend YieldN/ABeta1.68 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainShort InterestSocial Media Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingCronos Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.83, Cronos Group has a forecasted upside of 85.9% from its current price of $5.29.Amount of Analyst CoverageCronos Group has only been the subject of 1 research reports in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCronos Group has received 435 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCronos Group has received 507 “underperform” votes. (Add your “underperform” vote.)Community SentimentCronos Group has received 53.82% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote “Outperform” if you believe CRON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCronos Group does not currently pay a dividend.Dividend GrowthCronos Group does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cronos Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,700.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.93% of the stock of Cronos Group is held by insiders.Percentage Held by InstitutionsOnly 12.13% of the stock of Cronos Group is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cronos Group are expected to decrease in the coming year, from ($0.09) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cronos Group is 11.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Cronos Group is 11.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.37.Price to Book Value per Share RatioCronos Group has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.94 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRON Previous Symbol CUSIPN/A CIKN/A Webwww.thecronosgroup.com Phone416-504-0004Debt Debt-to-Equity Ratio0.01 Current Ratio5.96 Quick Ratio5.73Price-To-Earnings Trailing P/E Ratio11.76 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$25.64 million Price / Sales72.19 Cash Flow$0.74 per share Price / Cash Flow7.14 Book Value$5.01 per share Price / Book1.06Profitability EPS (Most Recent Fiscal Year)$0.67 Net Income$1.17 billion Net Margins1,729.07% Return on Equity-2.57% Return on Assets-2.17%Miscellaneous Employees291 Outstanding Shares349,886,000Market Cap$1.85 billion Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $5.29 +0.05 (+0.95 %) (As of 09/18/2020 09:20 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CRON News and Ratings via Email Sign-up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter. Cronos Group (NASDAQ:CRON) Frequently Asked Questions How has Cronos Group's stock price been impacted by COVID-19 (Coronavirus)? Cronos Group's stock was trading at $5.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRON stock has decreased by 2.2% and is now trading at $5.29. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cronos Group? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cronos Group. When is Cronos Group's next earnings date? Cronos Group is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Cronos Group. How were Cronos Group's earnings last quarter? Cronos Group Inc (NASDAQ:CRON) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.25. The firm had revenue of $9.88 million for the quarter, compared to analyst estimates of $12.29 million. Cronos Group had a net margin of 1,729.07% and a negative return on equity of 2.57%. The company's revenue was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.22 EPS. View Cronos Group's earnings history. What price target have analysts set for CRON? 9 Wall Street analysts have issued 1 year price targets for Cronos Group's stock. Their forecasts range from $6.50 to $17.00. On average, they expect Cronos Group's share price to reach $9.83 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View analysts' price targets for Cronos Group. Are investors shorting Cronos Group? Cronos Group saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 51,260,000 shares, an increase of 9.9% from the July 30th total of 46,660,000 shares. Based on an average daily volume of 4,880,000 shares, the days-to-cover ratio is presently 10.5 days. Currently, 29.0% of the company's shares are sold short. View Cronos Group's Short Interest. Who are some of Cronos Group's key competitors? Some companies that are related to Cronos Group include STADA Arzneimittel (STDAF), Canopy Growth (CGC), USANA Health Sciences (USNA), Aphria (APHA), Aphria (APHA), Aurora Cannabis (ACB), Tilray (TLRY), Canopy Rivers (RIV), Chromadex (CDXC), Mediwound (MDWD), Charlie's (CHUC), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), FSD Pharma (HUGE) and Mannatech (MTEX). View all competitors. What other stocks do shareholders of Cronos Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Tilray (TLRY), Aphria (APHA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and OrganiGram (OGI). Who are Cronos Group's key executives? Cronos Group's management team includes the following people: Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)Mr. David Hsu, Chief Operating OfficerMs. Xiuming Shum, Gen. Counsel & Corp. Sec.Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.Mr. William Hilson, Chief Commercial Officer What is Cronos Group's stock symbol? Cronos Group trades on the NASDAQ under the ticker symbol "CRON." Who are Cronos Group's major shareholders? Cronos Group's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.53%), FMR LLC (0.31%), FMR LLC (0.31%), Swiss National Bank (0.23%), Man Group plc (0.20%) and TD Asset Management Inc. (0.17%). View institutional ownership trends for Cronos Group. Which institutional investors are selling Cronos Group stock? CRON stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Goldman Sachs Group Inc., Gerber Kawasaki Wealth & Investment Management, Advisor Group Holdings Inc., APG Asset Management N.V., Zurcher Kantonalbank Zurich Cantonalbank, Asset Management Corp IL ADV, and State of Wisconsin Investment Board. View insider buying and selling activity for Cronos Group. Which institutional investors are buying Cronos Group stock? CRON stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, FMR LLC, Man Group plc, Virtu Financial LLC, Wedbush Securities Inc., Mn Services Vermogensbeheer B.V., Marshall Wace LLP, and Toronto Dominion Bank. View insider buying and selling activity for Cronos Group. How do I buy shares of Cronos Group? Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cronos Group's stock price today? One share of CRON stock can currently be purchased for approximately $5.29. How big of a company is Cronos Group? Cronos Group has a market capitalization of $1.85 billion and generates $25.64 million in revenue each year. The company earns $1.17 billion in net income (profit) each year or $0.67 on an earnings per share basis. Cronos Group employs 291 workers across the globe. What is Cronos Group's official website? The official website for Cronos Group is www.thecronosgroup.com. How can I contact Cronos Group? Cronos Group's mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company can be reached via phone at 416-504-0004. This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
